Login

Financial Snapshot

Revenue
TTM
$0.00
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$1.902M
Current Assets
2025 Q2
$2.664M
Current Liabilities
2025 Q2
$10.52M
Current Ratio
2025 Q2
25.32%
Total Assets
2025 Q2
$3.797M
Total Liabilities
2025 Q2
$14.57M
Book Value
2025 Q2
-10.77M
Cash
Last 4 Quarters
N/A
P/E
Last 4 Quarters
N/A
Free Cash Flow
Last 4 Quarters
N/A

Stock Price

Loading...
Market Cap: $115.17 Million

About Alps Group Inc

Alps Group, Inc. operates as a biotechnology company that integrates research and development, medical services, and wellness solutions. The firm has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The firm provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. The company operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory.

Industry: Services-Health Services

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support